SynthesisHaematologica2013

Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis.

Ronit Gurion et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.